Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer

A. Drilon, G. R. Oxnard, D. S.W. Tan, H. H.F. Loong, M. Johnson, J. Gainor, C. E. McCoach, O. Gautschi, B. Besse, B. C. Cho, N. Peled, J. Weiss, Y. J. Kim, Y. Ohe, M. Nishio, K. Park, J. Patel, T. Seto, T. Sakamoto, E. RosenM. H. Shah, F. Barlesi, P. A. Cassier, L. Bazhenova, F. De Braud, E. Garralda, V. Velcheti, M. Satouchi, K. Ohashi, N. A. Pennell, K. L. Reckamp, G. K. Dy, J. Wolf, B. Solomon, G. Falchook, K. Ebata, M. Nguyen, B. Nair, E. Y. Zhu, L. Yang, X. Huang, E. Olek, S. M. Rothenberg, K. Goto, V. Subbiah, A. Drilon

Research output: Contribution to journalArticlepeer-review

104 Citations (Scopus)

Abstract

BACKGROUND RET fusions are oncogenic drivers in 1 to 2% of non-small-cell lung cancers (NSCLCs). In patients with RET fusion-positive NSCLC, the efficacy and safety of selective RET inhibition are unknown. METHODS We enrolled patients with advanced RET fusion-positive NSCLC who had previously received platinum-based chemotherapy and those who were previously untreated separately in a phase 1-2 trial of selpercatinib. The primary end point was an objective response (a complete or partial response) as determined by an independent review committee. Secondary end points included the duration of response, progression-free survival, and safety. RESULTS In the first 105 consecutively enrolled patients with RET fusion-positive NSCLC who had previously received at least platinum-based chemotherapy, the percentage with an objective response was 64% (95% confidence interval [CI], 54 to 73). The median duration of response was 17.5 months (95% CI, 12.0 to could not be evaluated), and 63% of the responses were ongoing at a median follow-up of 12.1 months. Among 39 previously untreated patients, the percentage with an objective response was 85% (95% CI, 70 to 94), and 90% of the responses were ongoing at 6 months. Among 11 patients with measurable central nervous system metastasis at enrollment, the percentage with an objective intracranial response was 91% (95% CI, 59 to 100). The most common adverse events of grade 3 or higher were hypertension (in 14% of the patients), an increased alanine aminotransferase level (in 12%), an increased aspartate aminotransferase level (in 10%), hyponatremia (in 6%), and lymphopenia (in 6%). A total of 12 of 531 patients (2%) discontinued selpercatinib because of a drug-related adverse event. CONCLUSIONS Selpercatinib had durable efficacy, including intracranial activity, with mainly lowgrade toxic effects in patients with RET fusion-positive NSCLC who had previously received platinum-based chemotherapy and those who were previously untreated. (Funded by Loxo Oncology and others; LIBRETTO-001 ClinicalTrials.gov number, NCT03157128.).

Original languageEnglish
Pages (from-to)813-824
Number of pages12
JournalNew England Journal of Medicine
Volume383
Issue number9
DOIs
Publication statusPublished - Aug 27 2020

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint

Dive into the research topics of 'Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer'. Together they form a unique fingerprint.

Cite this